Innovative Product LaunchPRCT's new robot Hydros represented 80% of the US systems sold in Q3, indicating strong future demand.
Regulatory MilestonesPRCT received FDA approval to initiate a pivotal study of Aquablation in prostate cancer, representing an incremental positive for the stock.
Revenue GrowthPRCT's revenue of approximately $58.4 million exceeded expectations, showcasing strong system placements and confidence in higher system ASPs.